Omeros Director Sells $59,000 in Stock (OMER)
Omeros (NASDAQ:OMER) Director Thomas J. Cable unloaded 5,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $11.80, for a total transaction of $59,000.00. Following the completion of the sale, the director now directly owns 62,067 shares in the company, valued at approximately $732,391. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
A number of analysts have recently weighed in on OMER shares. Analysts at Needham & Company LLC reiterated a “buy” rating on shares of Omeros in a research note on Monday, April 7th. They now have a $17.00 price target on the stock, up previously from $15.00. Separately, analysts at WBB Securities raised their price target on shares of Omeros from $20.00 to $30.00 in a research note on Monday, April 7th. They now have a “strong-buy” rating on the stock.
Omeros (NASDAQ:OMER) traded up 4.91% on Wednesday, hitting $11.97. 398,599 shares of the company’s stock traded hands. Omeros has a 1-year low of $4.54 and a 1-year high of $14.69. The stock’s 50-day moving average is $11.61 and its 200-day moving average is $11.25. The company’s market cap is $405.9 million.
Omeros (NASDAQ:OMER) last announced its earnings results on Monday, May 12th. The company reported ($0.45) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.45). The company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.45 million. During the same quarter last year, the company posted ($0.40) earnings per share. Omeros’s revenue was down 90.9% compared to the same quarter last year. On average, analysts predict that Omeros will post $-1.52 earnings per share for the current fiscal year.
Omeros Corporation operates as a biopharmaceutical company focused on the discovery, development and commercialization of products focused on inflammation and disorders of the central nervous system.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.